No defects have been reported in moderately severe type 1 von Willebrand disease (vWD) with a clear autosomal dominant inheritance pattern, and the mechanism underlying this form of vWD remains obscure. We have studied a type 1 vWD family with such a dominant phenotype. The entire coding sequence of the von Willebrand factor (vWFI gene was analyzed by direct sequencing of DNA fragments amplified by polymerase chain reaction. Only one candidate mutation T(3445) -C in exon 26 was detected that predicts a replacement of cysteine (C) at position 386 of the mature vWF subunit by arginine (R). Both mutant and normal vWF alleles were expressed as shown by analysis of platelet mRNA. This substitution segregates with vWD in the family and was not found in 100 unrelated individuals. The recombinant mutant vWF(C386R) was characterized by expression in 293T cells. The secretion of vWF(C386R) was greatly im-ON WILLEBRAND DISEASE (vWD) is a heteroge-
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V neous, hereditary bleeding disorder caused by an abnormality in the activity or quantity of the multimeric von Willebrand factor (vWF) protein. vWD is usually classified in three major categories, which may be subdivided in a large variety of clinical subtypes. Type 2 comprises all functional or qualitative variants, and the types 1 and 3 designate the quantitative defects. Type 1 vWD is the most common form' and refers to partial quantitative deficiency of vWF.' Type 3 vWD refers to virtually complete absence of vWF. ' Progress has been made in recent years in the characterization of the molecular basis of vWD. The majority of defects was detected in types 2A, 2B, and 2N (Normandy) vWD, which are characterized by missense mutations that are clustered in relatively small parts of the vWF gene that code for domains with a specific f~n c t i o n .~.~ In severe type 3 vWD, which is considered to be a recessive disorder, gene deletions. frameshift mutations, nonsense mutations, and defects of mRNA expression have been documented, either in homozygous or compound heterozygous form^.^.^.'^ The heterozygous relatives of those type 3 patients may have a completely normal phenotype or mildly reduced vWF parameters. Most of the carriers of null alleles are a~ymptomatic,'-'~ but some have mild symptoms and are designated as type 1 vWD."~"~'~ The penetrance of type 1 vWD, however, is variable and generally low in these families. Some of the variable penetrance may, in fact, be caused by occult compound heterozygosity as we have previously de~cribed.','~ However, some families with type 1 vWD display a clearly autosomal dominant inheritance pattern with high penetrance and are characterized by very low vWF parameters and moderately severe bleeding symptoms. This phenotype is different from the carriers of null alleles and therefore the mechanism underlying this form of vWD is probably also different. We hypothesized that the classical dominant type 1 phenotype with high penetrance is caused by a mutation resulting in a defective vWF subunit that interferes with the normal subunits coded for by the normal allele (a domipaired due t o retention in the endoplasmic reticulum. In cotransfections of normal and mutant vWF constructs, the vWF(C386R) subunits caused a dose-dependent decrease in the secretion of vWF. The multimer pattern remained nearly normal and consistent with a dominant vWD type 1 phenotype. The importance of the cysteine residues in the D3 domain of vWF in the pathogenesis of dominant type l vWD was further shown by the detection of another cysteine mutation, Cys3" + Phe, in two additional unrelated patients with a similar dominant type 1 vWD phenotype. We conclude that the loss of cysteine pairing in the D3 domain, leaving one free cysteine, can induce a purely quantitative deficiency of vWF by dominantly suppressing the secretion of normal vWF. 0 1996 by The American Society of Hematology.
nant-negative defect). To test this hypothesis we sequenced the entire coding region including splice junctions in four individuals from a family with an unambiguous dominant inheritance pattern of type 1 vWD. We detected a candidate mutation T(3445) -+ C in exon 26 that predicts a replacement of Cys3*' of the mature vWF subunit by Arg. This mutation was characterized by expression of the corresponding mutant recombinant VWF(C386R). In two additional unrelated type 1 vWD patients with a similar phenotype we also detected mutated cysteine residues in the D3 domain of vWF. inheritance. Laboratory data are summarized in Table 1 . In addition, 5 unrelated Dutch and 11 unrelated Italian patients with dominant type 1 vWD, which are phenotypically similar to the family described above, were studied.
Protein gel electrophoresis and immunoassay. Analysis of plasma vWF multimers was performed by sodium dodecyl sulfate (SDS)-agarose gel electrophoresis, using a modification of previously described methods.'"'' Transfer was performed to nitrocellulose filter (BA85; Schleicher & Schuell, Dassel, Germany) using a Trans-Blot Cell (Bio-Rad, Richmond, CA) at 30 V for 15 hours with cooling at 8°C. The vWF multimers were visualized by an immunoenzymatic alkaline phosphatase staining method (ProtoBlot, Western Blot AP, rabbit; Promega, Madison, WI) in accordance with the manufacturers technical manual. Analysis of recombinant vWF (rvWF) multimers and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) were performed as described."-*' Polyacrylamide gels containing "S-labeled samples were fixed, treated with Amplify (Amersham, Cleveland, OH), dried, and exposed to Kodak XAR-5 film (Eastman Kodak, Rochester, NY). Recombinant vWF antigen was measured by an enzyme linked immunosorbent assay (ELISA) using polyclonal rabbit anti-human vWF antibody 082 and peroxidase-conjugated rabbit anti-human VWF antibody P226 (DAKO, Carpinteria, CA).*'
Haplotypes were determined using the tetranucleotide variable number tandem repeat (VNTR) polymorphism in intron 40 of the vWF gene and two restriction fragment length polymorphisms (RFLP) in exon 18 and exon 28 as described." 24 Genomic DNA was prepared from peripheral blood leukocytes and was amplified by the polymerase chain reaction (PCR) as previously described.13 The conditions of the PCR were: denaturing at 94°C for 4 minutes, followed by 32 cycles of 1-minute melting at 94°C I-minute annealing at 58T, and 2-minute extension at 72°C. All exons, except 19 to 23, were amplified from genomic DNA using intronic oligonucleotide primers flankmg the coding sequences. Exons 19 to 23 were amplified from cDNA that was synthesized from platelet-derived RNA. Exon 28 was amplified in two overlapping fragments using flanking and internal primers. Some pairs of exons were amplified as one fragment spanning the intervening intronic sequence (exons 4-5,29-30,39-40,49-50,51-52). The oligonucleotide primers were designed based on the reported sequences of the vWF geneZS and pseudogene.z6 To prevent inadvertent amplification of the vWF pseudogene, primers were chosen to contain one or more mismatches with the vWF pseudogene sequence. Some primer sequences of importance are listed in Table 2 . The other primer sequences may be obtained from the corresponding author.
Cytoplasmic RNA was extracted from platelets isolated from a blood sample of 25 mL collected in 0.1 1 mom sodium Platelet RNA was used as template in the cDNA synthesis reaction, which was subsequently amplified by PCR as de~cribed.'~ Primers used for the reverse transcription and cDNA-dependent PCR reactions are listed in Table 2 .
PCR fragments were excised from ultra-low Haplotype analysis.
Amplij'ication of genomic DNA and RNA.
Sequence analysis.
gelling temperature agarose (Sigma Chemical Co, St Louis, MO). The fragments were directly sequenced by the dideoxynucleotide chain-termination method (MI3 sequencing kit; Boehringer Mannheim, Mannheim, Germany) using the PCR primers or internal oligonucleotide primers. Plasmid construction. Plasmid pSVHVWFl contains a fulllength normal human vWF cDNA cloned into the expression vector pSV7DZ8 as described." Plasmid pSVHC386R contains a T to C transition at nucleotide 3445 resulting in a substitution of Cys by Arg at amino acid 386 of the mature vWF. pSVHC386R was constructed from pSVHVWFl by PCR-based mutagenesis. The method was essentially the same as previously described," but using 5'-GGC GCT ATA ACA GCc GTG CAC CTG CCT GTC AAG T-3' as the mutagenic primer (vWF nucleotides 343 1 to 3464 complement, substitution in lower case).
COS-7 monkey kidney cells or 293T human kidney cells30 (kindly provided by Dr D. Ginsburg, University of Michigan, Ann Arbor) were transiently transfected with plasmids pSVHVWFl (wild type) and pSVHC386R (mutant) using a calcium phosphate method'' and culture conditions described p r e v i o~s l y .~~ Twenty-four hours after transfection, cells were washed once with phosphate-buffered saline (PBS), and then incubated with 10 mL serum-free medium (Optimem-1 ; GIBCO, Gaithersburg. MD). Recombinant vWF secreted in the medium and retained in cell lysate was obtained as described.33 Briefly, cell culture medium was collected into a final concentration of 5 mmol/L EDTA and 2 mmoVL phenylmethylsulfonyl fluoride (PMSF). Cell lysates were prepared in 4 mL of Nonidet P-40 (Sigma) lysis buffer (150 mmol/ L NaC1, 50 mmom Tris-HC1, pH 7.5, 0.5% SDS, 1% Nonidet P-40, 5 mmol/L EDTA, 2 mmol/L iodoacetic acid, and 2 mmol/L Nethylmaleimide) per 100-mm dish. PMSF at a final concentration of 2 mmol/L was added to all cell lysates. Expression levels in 293T cells were consistently 5-to IO-fold higher than in COS-7 cells.
Transfection efficiency was monitored by cotransfection with a
Expression of recombinant vWF. 
RESULTS
Patients, haplovpes, and mRNA expression. The laboratory data in Table 1 indicate that three family members (III-4, IV-l, and IV-2) are affected and have low vWF antigen and activity values that are independent of AB0 blood type. The pedigree of the family is shown in Fig 1 A. The proband 111-4 suffers from epistaxis and easy bruising, and experienced excessive bleeding after vasectomy, nail extraction, and ankle distortion. His two affected children, IV-1 and IV-2, bruise easily. but did not undergo any surgical intervention without prophylactic treatment. The unaffected individuals 111-5 and IV-3 are asymptomatic. Previous generations also showed a bleeding tendency. The mother of 111-4 bled excessively after tonsillectomy, tooth extraction, and after childbirth and bruised easily. Her father, the maternal grandfather of 111-4, was known to have had abnormal bleeding after tooth extraction and prolonged bleeding from small wounds. The patients' plasma vWF exhibits all sizes of vWF multimers in reduced amounts (Fig 2) with a slightly more pronounced decrease in the concentration of the largest forms that is not sufficient to indicate a qualitative vWF abnormality. Based on these phenotypic data this family is classified as dominant type 1 vWD with high penetrance.
The dominant inheritance pattern was confirmed by haplotype analysis (Fig I) . All three affected family members, with similar phenotypes, share the same vWF allele, but they all have a different second vWF allele. To comply with the hypothesis of a dominant-negative defect both vWF alleles must be expressed at the mRNA level. Therefore, we synthesized vWF cDNA from platelet-derived RNA, using primers 22 and 374 (Table 2) . Two cDNA fragments were amplified by PCR with primer pairs 17A-22 (exons 17 to 22) and 3570-374A (exons 27 to 28). To enhance specificity, the 17A-22 fragment was amplified in a nested PCR for 13 cycles using primers 17 and 22. In these fragments two coding polymorphisms were tested: the Rsa I polymorphism in exon 18 (fragment polymorphism in exon 18 is also shown by direct sequence analysis of the cDNA fragment 17-22 (Fig 1 B, lower panel) .
Identificcrtion of candielate mutations. We sequenced the entire coding sequence of the vWF gene. excluding the untranslated exon 1. Exons 18, 19, 20 , and 21 were sequenced using the above-mentioned cDNA fragment 17-22. Exons 22 and 23 were analyzed in a cDNA fragment amplified by primers 20 and 24. All other exons were amplified from genomic DNA and directly sequenced. Because we anticipated the possibility of finding several polymorphisms and to minimize sequence errors, we sequenced four of the family members in parallel (genomic DNA fragments of 111-4, Ill-S. IV-l , and IV-2; cDNA fragments of 111-4, W-1. IV-2, and IV-3). This enabled us to assign the polymorphisms to a EIKENBOOM ET AL specific allele and to improve the interpretation of artifacts related to the sequence reactions.
All amplifications of exons with corresponding sequences in the vWF pseudogene proved gene specific on sequence analysis. We identified several sequence variations, most of which have already been reported (Table 3 and refs 14 and  36) . We identified only one candidate mutation, T(344S) + C in exon 26. that predicts a replacement in the mature vWF subunit of Cys"" by Arg (amino acid I149 from the methionine initiator codon). The substitution was confirmed by A h I digestion and shown to segregate with vWD in the family (Fig 3) . The affected mother of 111-4 also carried the mutation (data not shown). The CY^'^'' + Arg mutation was not found in 100 normal unrelated individuals tested by A h I digestion of PCR products.
We have sequenced exons 24 to 27 in an additional panel of S unrelated Dutch and I 1 unrelated Italian patients with dominant type 1 vWD. In 2 of the Italian patients we found a candidate mutation, G(3389) + T. that predicts the substitution of another cysteine residue.
-+
Phe. The results of the sequence reaction were confirmed by F w 4 H I digestion (Fig 4) . Fifty normal unrelated individuals were tested by Fnrr4H I digestion for the presence of the substitution G(3389) + T, but they all showed the normal restriction pattern.
E.rpre.s.sion m d ckcrrcrcteri~crtior~ ofn~WF(C386R). 293T cells were transiently transfected
with plasmids encoding wild-type vWF or vWF(C386R). and rvWF was quantitated in culture medium and cell lysates by ELISA. Wild-type rvWF was secreted efficiently, achieving a concentration of 1.28 2 0.08 pg/mL (range of duplicates) in conditioned medium compared with 0. I2 2 0.02 pg/mL in cell lysates. In contrast, rvWF(C386R) was secreted poorly, reaching a concentration of only 0.15 2 0.02 pg/mL in conditioned medium, and OS7 2 0.08 pglmL in cell lysates. Similar results were obtained upon transfection of COS-7 cells (data not shown).
The impaired secretion of rvWF(C386R) was studied in more detail by pulse-chase labeling (Fig S) . Within 30 rninUtes, wild-type rvWF was detected within cells as an = M OkD species that was converted to an a2SO-kD species and secreted during the following 6 to48 hours. This is consistent with the known pathway of vWF synthesis by endothelial cells, in which dimers of pro-vWF in the endoplasmic reticulum are transported to the Golgi, where the propeptide is removed and multimers are assembled before secretion.37 A qualitatively similar pattern was observed for rvWF(C386R). except that pro-vWF(C386R) accumulated within the cell and little mature vWF was secreted. These data suggest mutant rvWF(C386R) subunits are retained and degraded within the endoplasmic reticulum.
To mimic the type 1 phenotype caused by heterozygosity for the Cys"" + Arg substitution, wild-type vWF and mutant vWF(C386R) plasmids were cotransfected in 293T cells. For a fixed amount of wild-type plasmid. increasing amounts of mutant plasmid caused a dose-dependent inhibition of vWF secretion ( Fig 6A) and a corresponding increase in the level of intracellular vWF (Fig 6B) . At the highest concentration of mutant plasmid.
vWF secretion was inhibited =W%.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Transfection with increasing amounts of wild-type vWF plasmid did not impair secretion or cause intracellular retention of vWF, indicating that the effects caused by cotransfection with mutant plasmid were specific for the C386R substitution. Despite variations in vWF, the expression of growth hormone was nearly constant in all transfections, indicating that variations in transfection efficiency do not account for the results. These data are consistent with the proposed dominant-negative effect of the vWF(C386R) mutation in vivo.
The decrease in vWF secretion in cotransfection experiments was less than the decrease in plasma vWF of patients with this mutation, indicating that transiently transfected 293T cells do not fully recapitulate the processes that contribute to the biologic phenotype. The multimer pattern of secreted rvWF was analyzed to confirm that the vWF(C386R) mutation is compatible with vWD type 1 (Fig 7) . Transfection of 293T cells with the mutant vWF(C386R) plasmid alone led to the secretion of scant amounts of small vWF multimers that were visualized after appropriate concentration of the culture medium. Transfection of increasing amounts of mutant plasmid caused a slight, dose-dependent decrease in the concentration of the largest vWF multimers, producing a pattern like that of plasma vWF from affected family members (Fig 2) . zygosity or compound heterozygosity for vWF null allele^.'."'^ Although the heterozygous carriers of these null alleles often are a~ymptomatic,"'~ some mildly symptomatic carriers were identified and classified as vWD type 1.".12.'4 This mild type 1 phenotype can be found in more than one generation, but penetrance is low. In this study we focused on a different vWD type 1 phenotype characterized by more severe bleeding symptoms, very low levels of vWFAg and vWFRCO, and a clear autosomal dominant inheritance pattem with high penetrance in each generation. Molecular defects causing this type 1 phenotype have not been characterized. Because null alleles are associated with no or only a mild reduction of v W F values, we hypothesized that the more severe dominant type 1 phenotype might be explained by a functionally abnormal vWF subunit that interferes with the normal vWF subunit expressed from the other allele, thereby causing a dominant-negative defect.
To test this concept we selected a family that satisfied these criteria for moderately severe, autosomal dominant type 1 vWD with high penetrance. A prerequisite for the proposed mechanism is that the mutant allele cannot be a null allele but must be expressed. This was confirmed at the level of transcription by analysis of polymorphisms in cDNA synthesized from platelet derived vWF mRNA: both alleles were detected at similar levels in samples from affected patients (Fig 1) .
By determining the entire coding sequence of the mutant vWF gene in this family, a single candidate mutation was identified: a T(3445) + C transition that predicts the substitution of CYS''~ by Arg (Fig 3) . Much evidence supports the causative nature of this mutation. First, no nonsense or frameshift mutations were found, and all other amino acid substitutions identified were polymorphisms previously found in normal alleles (Table 3) . Second, this substitution was present in all affected individuals and was not found in 200 normal alleles. Finally, expression of mutant rvWF(C386R) showed that this mutation causes a decrease of -88% in the amount of vWF secreted. Substantial levels of mutant subunit were synthesized but were retained within the endoplasmic reticulum as pro-vWF subunits (Fig 5) . Thus, the vWF(C386R) mutation is compatible with high levels of gene transcription and mRNA translation, but is sufficient to cause markedly reduced secretion of functional vWF. More importantly, coexpression of vWF(C386R) subunits inhibited the secretion of normal vWF (Fig 6) with only a slight alteration of the vWF multimer distribution (Fig 7) similar to that observed in plasma v W F from affected patients (Fig 2) . These results support the hypothesis that the vWF(C386R) allele inhibits the function of a coinherited normal allele, thereby causing a moderately severe, dominant form of vWD type 1.
The defect in biosynthesis and secretion of vWF(C386R) suggests a general mechanism by which mutations may cause dominant vWD type I . In the rough endoplasmic reticulum, mutant and wild-type pro-vWF subunits may form both homodimers and heterodimers. This assumption is reasonable, because dimerization requires the = 15 l carboxylterminal amino acid residues of vWF and is independent of other domains." For a random dimerization process, only one in four pro-vWF dimers will contain either two wildtype subunits or two mutant subunits; two in four will be heterodimers. Retention of all mutant subunits in the endoplasmic reticulum then would reduce the transport of wildtype subunits to the Golgi apparatus by =50%, and those arriving in the Golgi could assemble into large multimers and be secreted normally. This hypothesis is consistent with the properties of recombinant vWF(C386R), particularly its ability to inhibit the secretion of wild-type vWF up to -35% in cotransfections (Fig 6) . and with the vWD type 1 phenotype of patients heterozygous for vWF(C386R): greater than 50% reduction of vWF levels, a nearly normal multimeric pattern, and autosomal dominant inheritance.
A critical feature of this model is that dominant vWD type 1 subunits should not interfere with multimer assembly or export from the Golgi, because this would cause the preferential secretion of small multimers and produce a qualitative (type 2A) defect. In fact, a class of dominant vWD type 2A mutations is compatible with the transport of mutant subunits to the Golgi, where they inhibit multimer assembly.3' A simple way to avoid this outcome is to impair the exit of mutant subunits from the endoplasmic reticulum, as shown for recombinant vWF(C386R) (Fig 5) . The efficiency with which mutant subunits interact with normal subunits in the Golgi should determine whether the corresponding phenotype is mainly quantitative or qualitative deficiency. In general, failure to reach the Golgi would be associated with a quantitative (type 1) defect, whereas arrival in the Golgi would be predicted to cause a qualitative (type 2) defect.
The dominant vWD type 1 mutation vWF(C386R) and vWD type 2A mutations may be considered to represent these extremes, and mutations with intermediate properties are likely to be identified among patients with confusing or indeterminate phenotypes.
Missense mutations in vWF that cause distinct variants of vWD often appear to cluster in discrete regions of the protein. For example, almost all dominant vWD type 2A muta- For personal use only. on October 3, 2017. by guest www.bloodjournal.org From tions are located within the second repeated A domain of vWF, between mature subunit residues 717 and 909. By analogy to forms of type 2 vWD associated with clustered mutations, we suggest that mutations for dominant type 1 vWD also may cluster in a region that, when disrupted, promotes the retention of vWF subunits in the endoplasmic reticulum. The first such mutation, vWF(C386R), is in the D3 domain of the vWF. The D3 domain, situated in the amino-terminal region of the mature vWF subunit, contains many cysteine residues"-41 and is involved in the assembly of pro-vWF dimers into m~ltimers.~**~' Cys3" forms a disulfide bridge with Cysa. It is not known whether this is an intrachain or interchain disulfide bond.44 Mutation of C Y S~'~ leads to the loss of this disulfide bridge and should create an unpaired cysteine residue; this may sufficiently alter the structure of vWF to account for the intracellular retention of mutant subunits. Accordingly, we screened exons 24 to 27, which contain the highest percentage of cysteine residues in the D3 domain, for the presence of mutations in a panel of 16 patients with dominant type 1 vWD. Indeed, we identified a substitution in two additional unrelated patients: G(3389) -+ T. This mutation predicts the change of C~S ' '~ in the mature subunit to Phe and results in the loss of the intrachain disulfide pairing with CYS'~~."
To conclude, we detected the loss of two different cysteine residues in the D3 domain of vWF in three unrelated dominant type 1 vWD patients. We demonstrated by in vitro expression of the mutant rVWF(C386R) that this mutation causes a secretory defect with intracellular retention of the mutant subunits. This indicates that a structural defect of the vWF subunit may induce dominant quantitative vWF deficiency in plasma.
